Image
Clinical Research Updates

Clinical Updates in Non-Small Cell Lung Cancer

Guidelines

NCCN Clinical Practice Guidelines in Oncology: Non-small Cell Lung Cancer (version 4), 2015

NCCN Guidelines for Patients: Non-small Cell Lung Cancer (version 1), 2014

General Resources

Lung Cancer Alliance

Founded in 1995, Lung Cancer Alliance is the oldest and leading non-profit organization dedicated to saving lives and advancing research by empowering those living with and at risk for lung cancer.

American Cancer Society

For over 100 years, the American Cancer Society has worked relentlessly to save lives and create a world with less cancer. Together with millions of our supporters worldwide, we help people stay well and get well, find cures, and fight back against cancer. 

National Cancer Institute

The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Suggested Readings

Update on Immune Checkpoint Inhibitors in Lung Cancer

Creelan BC. Cancer Control. 2014;21(1):80-89

Immune Checkpoints in Cancer Clinical Trials.

Sharon E, et al. Chin J Cancer. 2014;33(9):434-444.

Review of the current targeted therapies for non-small-cell lung cancer.

Nguyen KS, et al. World J Clin Oncol. 2014;5(4):576-587.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Herbst RS, et al. Nature. 2014;515(7528):563-567.

A Phase I open-label study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death-ligand 1(PD-L1) antibody, in combination with tremelimumab in patients with advanced Non-small cell lung cancer.

Antonia S, et al. Ann Oncol. 2014;25(suppl 4; abstr 1327P).

Efficacy and safety of ceritinib in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): An Update of ASCEND-1

Felip E, et al. Ann Oncol. 2014;25(suppl 4; abstr 1295P).

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study

Gadgeel S, et al. Lancet. 2014;15(10):1119-1128.

Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer

Soria J-C, et al. Euro J Cancer. 2014;50(suppl 6):199.

Updated safety and efficacy from a phase I study of AZD9291 in patients (pts) with EGFR-TKI-resistant non-small cell lung cancer (NSCLC).

Yang JC, et al. Ann Oncol. 2014;25(suppl 4; abstr 449PD).

Interactive Presentation

Clinical Updates in Non-Small Cell Lung Cancer (NSCLC)

Roy S. Herbst, MD, PhD; Roman Perez-Soler, MD; Gregory J. Riely, MD, PhD


Activity
Clinical Updates in Non-Small Cell Lung Cancer

New Management Strategies to Improve Patient Outcomes

Relevant Resources

Comprehensive Relief from Cancer Pain

Expanding the Conversation on Opioid-Induced Constipation